Phase 4 Pulmonary Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 18 and 80 years old
- You are able to understand and sign a consent form agreeing to take part
- You have been diagnosed with pulmonary arterial hypertension (high blood pressure in the lungs) that is either inherited, has no known cause, or was caused by certain drugs, toxins, or a connective tissue disease (such as lupus or scleroderma)
- You have been on a stable combination of approved lung blood pressure medications (called ERAs and PDE5 inhibitors) for at least 1 month before the study screening (unless you were unable to tolerate these medications)
- Your condition is classified as WHO functional class III, meaning symptoms significantly limit your physical activity
- Your right heart catheterisation (a test measuring pressures in the heart and lungs) showed specific pressure and resistance readings at the time of your diagnosis (confirm with trial site)
- You are able to walk more than 50 metres in a 6-minute walking test
- Your kidneys are working at an adequate level, based on a blood test result (confirm with trial site)
- Your doctor has determined that your current treatment is not working well enough
Who may not be able to join:
- You are unable to understand or sign a consent form
- You are currently pregnant
- You have ever had a blood clot in the lungs that happened without a clear cause
- You have an active infection at the time of screening (though you may be able to rescreen once the infection has cleared)
- Your pulmonary arterial hypertension is related to HIV, liver disease, a parasitic infection called schistosomiasis, or a heart defect you were born with
- Your high lung blood pressure is caused by left-sided heart problems, lung disease, blood clots, or other mixed causes
- You are unable to tolerate aspirin or a type of blood-thinning medication called a P2Y12 inhibitor (such as clopidogrel)
- You have a known allergy or serious reaction to the study drugs selexipag or riociguat
- Your kidneys are not functioning well enough, based on a blood test result (confirm with trial site)
- You have anaemia, meaning your blood count (haemoglobin) is below a certain level
- You have significant heart valve problems or other serious heart conditions affecting the left side of your heart (confirm with trial site for specific details)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Alexander Rothman, MD / PhD, University of Sheffield
Phone: +44 (0) 114 2159550
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Right Ventricular Stroke Volume (RVSV) flow on each therapy measured by MRI RSVS (flow) on each therapy measured by MRI
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.